Sanofi sets up a ti­tle fight with Roche in he­mo­phil­ia A — pro­vid­ed gene ther­a­pies don't beat them to the punch

Af­ter get­ting roughed up by Roche’s block­buster he­mo­phil­ia A drug Hem­li­bra, Sanofi is plan­ning to hit back with its own com­mer­cial coun­ter­punch fol­low­ing pos­i­tive Phase III da­ta for the Fac­tor VI­II re­place­ment drug efane­soc­tocog al­fa (BIVV001).

The phar­ma gi­ant, paired with So­bi on this one, re­port­ed a 0 me­di­an an­nu­al­ized bleed rate for pa­tients on their drug us­ing a once-week­ly dos­ing sched­ule, with a 0.71 mean ABR, beat­ing out the pri­or drugs these pa­tients had been on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER